Table I.
Adjusted use of rasburicase by demographic category*
| ALL (n = 11,682) | NHL (n = 1,401) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | Prevalence of rasburicase use |
Crude OR of rasburicase use (95% CI) |
Adjusted OR of rasburicase use (95% CI)* |
P (adjusted) | N | Prevalence of rasburicase use |
Crude OR of rasburicase use (95% CI) |
Adjusted OR of rasburicase use (95% CI)* |
P (adjusted) |
|
| Age | ||||||||||
| 0 – <5 years | 5,579 | 748 (13.4%) | 183 | 72 (39.3%) | ||||||
| 5 – <10 years | 2,997 | 484 (16.2%) | 1.24 (1.10–1.41) | 1.29 (1.13–1.47) | <0.0001 | 374 | 148 (39.6%) | 1.01 (0.70–1.45) | 0.93 (0.60–1.42) | 0.724 |
| 10 – <15 years | 1,904 | 503 (26.4%) | 2.32 (2.04–2.63) | 2.36 (2.06–2.72) | <0.0001 | 429 | 143 (33.3%) | 0.77 (0.54–1.10) | 0.70 (0.46–1.06) | 0.095 |
| 15 – <22 years | 1,202 | 343 (28.5%) | 2.58 (2.23–2.99) | 2.85 (2.43–3.34) | <0.0001 | 415 | 96 (23.1%) | 0.46 (0.32–0.67) | 0.33 (0.21–0.52) | <0.0001 |
| Sex | ||||||||||
| Female | 5,169 | 776 (15.0%) | 340 | 84 (24.7%) | ||||||
| Male | 6,513 | 1,302 (20.0%) | 1.41 (1.28–1.56) | 1.33 (1.20–1.48) | <0.0001 | 1,061 | 375 (35.3%) | 1.67 (1.26–2.20) | 1.57 (1.13–2.18) | 0.007 |
| Race | ||||||||||
| Caucasian | 8,377 | 1,448 (17.3%) | 960 | 327 (34.1%) | ||||||
| African American | 867 | 216 (24.9%) | 1.59 (1.35–1.87) | 1.18 (0.97–1.42) | 0.093 | 126 | 39 (31.0%) | 0.87 (0.58–1.30) | 0.81 (0.49–1.32) | 0.392 |
| Other | 2,202 | 385 (17.5%) | 1.01 (0.90–1.15) | 1.00 (0.87–1.16) | 0.956 | 296 | 73 (29.7%) | 0.82 (0.62–1.09) | 0.81 (0.56–1.16) | 0.252 |
| Missing | 236 | 29 (12.3%) | 0.67 (0.45–0.99) | 0.99 (0.64–1.53) | 0.970 | 19 | 5 (26.3%) | 0.69 (0.25–1.94) | 1.07 (0.29–4.03) | 0.917 |
| Insurance | ||||||||||
| Private | 5,059 | 848 (16.8%) | 778 | 254 (32.7%) | ||||||
| Public | 5,012 | 951 (19.0%) | 1.16 (1.05–1.29) | 1.09 (0.97–1.23) | 0.136 | 491 | 161 (32.8%) | 1.01 (0.79–1.28) | 0.83 (0.61–1.12) | 0.226 |
| Other | 1,611 | 279 (17.3%) | 1.04 (0.90–1.21) | 0.89 (0.75–1.05) | 0.176 | 132 | 44 (33.3%) | 1.03 (0.70–1.53) | 1.08 (0.66–1.75) | 0.768 |
| ICU level care resources in first 48 h | ||||||||||
| No | 11,252 | 1,789 (15.9%) | 1,344 | 418 (31.1%) | ||||||
| Yes | 430 | 289 (67.2%) | 10.74 (8.81–13.34) | 13.43 (10.67–16.89) | <0.0001 | 57 | 41 (71.9%) | 5.68 (3.15–10.23) | 5.85 (2.93–11.68) | <0.0001 |
| Time to first rasburicase exposure, days | ||||||||||
| Range | 1 – 21 | 1 – 27 | ||||||||
| Mean | 1.99 | 3.51 | ||||||||
| Cumulative rasburicase exposure, days | ||||||||||
| Range | 0 – 9 | 0 – 8 | ||||||||
| Mean (in exposed patients) | 1.83 | 1.98 | ||||||||
*
Based on logistic regression model adjusted for hospital indicator, age, sex, race, insurance and presentation severity.
95% CI: 95% confidence interval; ICU: intensive care unit; OR: odds ratio.